Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara A Blodi

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Ophthalmology|November 20, 2016
SCORE2 Report 2: Study Design and Baseline CharacteristicsIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
JAMA Ophthalmology|May 11, 2023
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialSteven M Kymes, Neal L Oden, Paul C VanVeldhuisen, et al.
Translational Vision Science & Technology|November 4, 2024
Comparison of Geographic Atrophy Measurements Between Blue-Light Heidelberg Standard Field and Green-Light Optos Ultrawide Field AutofluorescenceColin P Froines, Thomas F Saunders, Jennifer A Heathcote, et al.
Ophthalmology|April 7, 2009
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion typeIngrid U Scott, Barbara A Blodi, Michael S Ip, et al.
Ophthalmology|October 8, 2010
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10Ingrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|February 25, 2018
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical TrialIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
Ophthalmology|January 27, 2009
SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusionIngrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|December 28, 2018
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 StudyMichael S Ip, Neal L Oden, Ingrid U Scott, et al.
JAMA Ophthalmology|October 28, 2021
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical TrialAhmad A Aref, Ingrid U Scott, Paul C VanVeldhuisen, et al.
Journal of Vitreoretinal Diseases|May 21, 2026
Impact of Aflibercept Dosing Frequency on Retinal Nonperfusion Progression Assessed by Ultra-Widefield Angiography After Endolaserless Vitrectomy for Proliferative Diabetic Retinopathy-Related Vitreous HemorrhageLuke G Qin, Nicholas D Camarda, Venkatkrish M Kasetty, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Ophthalmology|November 20, 2016
SCORE2 Report 2: Study Design and Baseline CharacteristicsIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
JAMA Ophthalmology|May 11, 2023
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialSteven M Kymes, Neal L Oden, Paul C VanVeldhuisen, et al.
Translational Vision Science & Technology|November 4, 2024
Comparison of Geographic Atrophy Measurements Between Blue-Light Heidelberg Standard Field and Green-Light Optos Ultrawide Field AutofluorescenceColin P Froines, Thomas F Saunders, Jennifer A Heathcote, et al.
Ophthalmology|April 7, 2009
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion typeIngrid U Scott, Barbara A Blodi, Michael S Ip, et al.
Ophthalmology|October 8, 2010
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10Ingrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|February 25, 2018
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical TrialIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
Ophthalmology|January 27, 2009
SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusionIngrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|December 28, 2018
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 StudyMichael S Ip, Neal L Oden, Ingrid U Scott, et al.
JAMA Ophthalmology|October 28, 2021
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical TrialAhmad A Aref, Ingrid U Scott, Paul C VanVeldhuisen, et al.
Journal of Vitreoretinal Diseases|May 21, 2026
Impact of Aflibercept Dosing Frequency on Retinal Nonperfusion Progression Assessed by Ultra-Widefield Angiography After Endolaserless Vitrectomy for Proliferative Diabetic Retinopathy-Related Vitreous HemorrhageLuke G Qin, Nicholas D Camarda, Venkatkrish M Kasetty, et al.
Pageof 9